全文获取类型
收费全文 | 121328篇 |
免费 | 10596篇 |
国内免费 | 7702篇 |
专业分类
耳鼻咽喉 | 1075篇 |
儿科学 | 1638篇 |
妇产科学 | 2318篇 |
基础医学 | 14002篇 |
口腔科学 | 2043篇 |
临床医学 | 14725篇 |
内科学 | 19210篇 |
皮肤病学 | 1397篇 |
神经病学 | 6678篇 |
特种医学 | 4299篇 |
外国民族医学 | 70篇 |
外科学 | 12912篇 |
综合类 | 18882篇 |
一般理论 | 5篇 |
预防医学 | 7517篇 |
眼科学 | 3623篇 |
药学 | 12540篇 |
80篇 | |
中国医学 | 6096篇 |
肿瘤学 | 10516篇 |
出版年
2024年 | 66篇 |
2023年 | 1643篇 |
2022年 | 2377篇 |
2021年 | 4553篇 |
2020年 | 4387篇 |
2019年 | 5096篇 |
2018年 | 3386篇 |
2017年 | 3610篇 |
2016年 | 3035篇 |
2015年 | 4916篇 |
2014年 | 6440篇 |
2013年 | 5972篇 |
2012年 | 8735篇 |
2011年 | 9552篇 |
2010年 | 5933篇 |
2009年 | 4721篇 |
2008年 | 6500篇 |
2007年 | 6492篇 |
2006年 | 6527篇 |
2005年 | 6480篇 |
2004年 | 4450篇 |
2003年 | 4208篇 |
2002年 | 3555篇 |
2001年 | 3211篇 |
2000年 | 3292篇 |
1999年 | 3424篇 |
1998年 | 2164篇 |
1997年 | 2110篇 |
1996年 | 1517篇 |
1995年 | 1453篇 |
1994年 | 1263篇 |
1993年 | 820篇 |
1992年 | 1225篇 |
1991年 | 1073篇 |
1990年 | 927篇 |
1989年 | 819篇 |
1988年 | 706篇 |
1987年 | 648篇 |
1986年 | 501篇 |
1985年 | 459篇 |
1984年 | 244篇 |
1983年 | 172篇 |
1982年 | 113篇 |
1981年 | 111篇 |
1980年 | 75篇 |
1979年 | 120篇 |
1978年 | 59篇 |
1976年 | 52篇 |
1975年 | 53篇 |
1974年 | 64篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Yan Gao MD Yizhen Liu MD PhD Yafei Wang MD Qingyuan Zhang MD Depei Wu MD Xu Ye MD Jianqiu Wu MD Wei Xu MD Jianfeng Zhou MD Yu Yang MD Hong Cen MD Feng Zhang MD Ying Xiang MD Xiaoqiong Tang MD Kaiyang Ding MD JinYing Lin MD Lei Ma MD Shunqing Wang MD Hao Yu MD Yang Zhao MD Bin Song MD Fangfang Lv MD Huiqiang Huang MD 《Cancer》2023,129(4):551-559
2.
3.
Shaked Lev-Ari MD Michael Serzan MD Tianmin Wu MS Andrew Ip MD Lauren Pascual HSD Brittany Sinclaire MS Shari Adams HSD Michael Marafelias BS Lakshmi Ayyagari MD Sarvarinder K. Gill MD Barbara Ma MD Jacob P. Zaemes MD Alexandra Della Pia PharmD Adil Alaoui MS Subha Madhavan PhD Anas Belouali MS Andrew Pecora MD Jaeil Ahn PhD Michael B. Atkins MD Neil J. Shah MD 《Cancer》2023,129(12):1885-1894
4.
Thomas Boerner Rebecca A. Carr Meier Hsu Alexa Michel Kay See Tan Elvira Vos Smita Sihag Manjit S. Bains Geoffrey Y. Ku Abraham J. Wu David R. Jones Daniela Molena 《International journal of cancer. Journal international du cancer》2023,152(10):2109-2122
Up to 50% of patients treated with curative esophagectomy for esophageal cancer will develop recurrence, contributing to the dismal survival associated with this disease. Regional recurrence may represent disease that is not yet widely metastatic and may therefore be amenable to more-aggressive treatment. We sought to assess all patients treated with curative esophagectomy for esophageal cancer who developed regional recurrence. We retrospectively identified all patients who underwent esophagectomy for esophageal adenocarcinoma and esophageal squamous cell carcinoma at a single institution from January 2000 to August 2019. In total, 1626 patients were included in the study cohort. As of June 2022, 595 patients had disease recurrence, which was distant or systemic in 435 patients (27%), regional in 125 (7.7%) and local in 35 (2.2%). On multivariable analysis, neoadjuvant chemoradiation with a total radiation dose <45 Gy (hazard ratio [HR], 3.5 [95% CI, 1.7-7.3]; P = .001), pathologic node-positive disease (HR, 1.9 [95% CI, 1.3-3.0]; P = .003) and lymphovascular invasion (HR, 1.6 [95% CI, 1.0-2.5]; P = .049) were predictors of isolated nodal recurrence, whereas increasing age (HR, 0.97 [95% CI, 0.96-0.99]; P = .001) and increasing number of excised lymph nodes (HR, 0.98 [95% CI, 0.95-1.00]; P = .021) were independently associated with decreased risk of regional recurrence. Patients treated with a combination of local and systemic therapies had better survival outcomes than patients treated with systemic therapy alone (P < .001). In patients with recurrence of esophageal cancer limited to regional lymph nodes, salvage treatment may be possible. Higher radiation doses and more-extensive lymphadenectomy may reduce the risk of regional recurrence. 相似文献
5.
Wuteng Cao Huabin Hu Jiao Li Qianyu Wu Lishuo Shi Biao Li Jie Zhou Xinhua Wang Junhong Chen Chao Wang Huaiming Wang Weihao Deng Yan Huang Yanhong Deng 《International journal of cancer. Journal international du cancer》2023,153(11):1894-1903
Neoadjuvant programmed cell death protein 1 (PD-1) blockade exhibits promising efficacy in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC). However, discrepancies between radiological and histological findings have been reported in the PICC phase II trial (NCT 03926338). Therefore, we strived to discern radiological features associated with pathological complete response (pCR) based on computed tomography (CT) images. Data were obtained from the PICC trial that included 36 tumors from 34 locally advanced dMMR CRC patients, who received neoadjuvant PD-1 blockade for 3 months. Among the 36 tumors, 28 (77.8%) tumors achieved pCR. There were no statistically significant differences in tumor longitudinal diameter, the percentage change in tumor longitudinal diameter from baseline, primary tumor sidedness, clinical stage, extramural venous invasion status, intratumoral calcification, peritumoral fat infiltration, intestinal fistula and tumor necrosis between the pCR and non-pCR tumors. Otherwise, tumors with pCR had smaller posttreatment tumor maximum thickness (median: 10 mm vs 13 mm, P = .004) and higher percentage decrease in tumor maximum thickness from baseline (52.9% vs 21.6%, P = .005) compared to non-pCR tumors. Additionally, a higher proportion of the absence of vascular sign (P = .003, odds ratio [OR] = 25.870 [95% CI, 1.357-493.110]), nodular sign (P < .001, OR = 189.000 [95% CI, 10.464-3413.803]) and extramural enhancement sign (P = .003, OR = 21.667 [2.848-164.830]) was observed in tumors with pCR. In conclusion, these CT-defined radiological features may have the potential to serve as valuable tools for clinicians in identifying patients who have achieved pCR after neoadjuvant PD-1 blockade, particularly in individuals who are willing to adopt a watch-and-wait strategy. 相似文献
6.
7.
目的观察老年冠心病患者移动健康管理模式的构建, 并进行实证研究。方法选取2019年1月至2021年1月于河南省人民医院接受治疗的86例老年冠心病患者, 随机数字表法分为两组, 每组各43例, 对照组实施常规干预, 观察组在常规干预基础上应用移动健康管理模式进行干预, 两组均干预3个月, 评估患者心绞痛情况、再入院危险因素控制评价指标达标情况[低密度脂蛋白胆固醇(LDL-C)、静息心率、收缩压、舒张压];于干预前、干预3个月, 评估患者自护能力。结果观察组心绞痛发作次数少于对照组[(0.53±0.18)次/周和(0.64±0.15)次/周, t=3.079, P=0.003], 持续时间短于对照组[(2.72±0.40)min和(3.06±0.55)min, t=3.278, P=0.002];观察组再入院危险因素LDL-C(90.7%比72.1%, χ2=4.914, P=0.027)、静息心率(95.4%比81.4%, χ2=4.074, P=0.044)、收缩压(86.1%比60.5%, χ2=7.182, P=0.007)、舒张压达标率(88.4%比67.4%, χ2=5.472... 相似文献
8.
目的分析老年综合评估(CGA)的开展现状。方法采用方便抽样的方法选取自2020年11月至2021年3月申请试用北京医院老年医学科研发的京颐汇老年综合评估系统的全国各地共191个科室进行调查。通过自设问卷调查科室基本情况、CGA开展情况和培训需求。结果 104个科室(54.5%)已开展CGA, 不同医院级别、医院所在地区和医院所在城市的科室开展CGA的比例差异无统计学意义。在已开展CGA的104个科室中, 28个科室(26.9%)开展了门诊CGA, 57个科室(54.8%)由科室随机人员完成CGA, 87个科室(83.7%)使用纸质问卷评估, 51个科室(49.0%)每月评估数量在10例以下。在未开展CGA的87个科室中, 68个科室(78.2%)存在无法收费问题, 64个科室(73.6%)存在缺乏专业人员问题。90%以上科室存在CGA的培训需求。结论 CGA的开展在我国尚处于起步阶段, 各地老年医学科开展CGA情况较差, 普遍面临无法收费、缺乏规范化的困境。 相似文献
9.
10.
Xu Li Peng Biao Wu Haiqiang Zheng Yike Yu Qingwen Fang Shuiqiao 《Metabolic brain disease》2022,37(4):1133-1143
Metabolic Brain Disease - Glioblastoma (GBM), a predominant central nervous system (CNS) malignancy, is correlated with high mortality and severe morbidity. Mammalian methyltransferase-like 7B... 相似文献